Anika Therapeutics (ANIK) Non-Current Deferred Tax Liability (2010 - 2023)

Anika Therapeutics (ANIK) has reported Non-Current Deferred Tax Liability for 14 consecutive years, with $2.0 million the latest figure, recorded in Q3 2023.

• On a quarterly basis, Non-Current Deferred Tax Liability fell 71.25% year-over-year to $2.0 million in Q3 2023; TTM through Sep 2023 was $2.0 million, a 71.25% decrease from a year earlier, with the FY2022 full-year figure at $6.4 million, down 36.63% from the prior year.
• Non-Current Deferred Tax Liability was $2.0 million for Q3 2023 at Anika Therapeutics, down from $3.2 million in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $16.0 million in Q1 2020 and troughed at $2.0 million in Q3 2023.
• A 5-year average of $8.4 million and a median of $8.2 million in 2022 frame the typical range for Non-Current Deferred Tax Liability.
• Across the five-year window, Non-Current Deferred Tax Liability soared 373.14% in 2020 and slumped 71.25% in 2023, its largest moves.
• Over 5 years, Non-Current Deferred Tax Liability stood at $4.3 million in 2019, then surged by 174.65% to $11.9 million in 2020, then fell by 14.61% to $10.2 million in 2021, then tumbled by 36.63% to $6.4 million in 2022, then tumbled by 69.62% to $2.0 million in 2023.
• The last three Non-Current Deferred Tax Liability figures came in at $2.0 million (Q3 2023), $3.2 million (Q2 2023), and $4.1 million (Q1 2023), per Business Quant data.